Future Directions for the Management of HR+ Breast Cancer
August 11th 2021Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Read More
Using CDK4/6 Inhibitors After HR+ mBC Disease Progression
July 21st 2021Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.
Read More
Role of Molecular Profiling in HR+ Metastatic Breast Cancer
June 30th 2021Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.
Read More
Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer
March 19th 2021Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.
Read More